Abivax $ABVX has still not been acquired. What's going on? Biotech M&A activity is off the charts, yet the French drugmaker — developer of o
Abivax $ABVX has still not been acquired. What's going on? Biotech M&A activity is off the charts, yet the French drugmaker — developer of obefazimod, a treatment for ulcerative colitis with blockbuster commercial potential — remains unbetrothed... The absence of said transaction has caused the stock's investor fanbase much grief and consternation. -- ADAM F STAT NEWS
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.